HRV Pharma Acquires German Firm Phatebo, Enters European Finished Formulations Market
Hyderabad-based HRV Pharma has acquired 100% equity in Germany's Phatebo GmbH from ZeroStack Corp, marking its entry into the European finished formulations market. Phatebo, founded in 2015 and based in Hilzingen, specialises in clinical trial supply and holds a licensed pharmaceutical wholesale authorisation in Germany. The acquisition expands HRV's portfolio beyond active pharmaceutical ingredients to include finished medicines, with Phatebo continuing operations under its existing management and customer agreements. Financial terms were not disclosed, and Phatebo reported revenues of approximately Rs 350 crore in 2025.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (56/100). Lens Score 38/100.
Outlets measured: moneycontrol, thehindu, businessstandard, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 3 Nov, 12:48 pm. Other outlets followed.